Silvercrest Asset Management Group LLC Makes New Investment in Fresenius Medical Care AG & Co. (NYSE:FMS)

Silvercrest Asset Management Group LLC purchased a new position in Fresenius Medical Care AG & Co. (NYSE:FMS) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 27,870 shares of the company’s stock, valued at approximately $1,095,000.

Other institutional investors have also made changes to their positions in the company. NEXT Financial Group Inc bought a new stake in shares of Fresenius Medical Care AG & Co. in the second quarter worth about $29,000. Lindbrook Capital LLC increased its holdings in shares of Fresenius Medical Care AG & Co. by 163.0% in the second quarter. Lindbrook Capital LLC now owns 781 shares of the company’s stock worth $30,000 after acquiring an additional 484 shares in the last quarter. Ashburton Jersey Ltd bought a new stake in shares of Fresenius Medical Care AG & Co. in the second quarter worth about $39,000. Tower Research Capital LLC TRC increased its holdings in shares of Fresenius Medical Care AG & Co. by 212.5% in the second quarter. Tower Research Capital LLC TRC now owns 1,078 shares of the company’s stock worth $42,000 after acquiring an additional 733 shares in the last quarter. Finally, Rehmann Capital Advisory Group increased its holdings in shares of Fresenius Medical Care AG & Co. by 46.7% in the first quarter. Rehmann Capital Advisory Group now owns 2,565 shares of the company’s stock worth $104,000 after acquiring an additional 817 shares in the last quarter. Institutional investors own 1.46% of the company’s stock.

Shares of FMS stock traded down $0.53 on Friday, hitting $34.49. 5,227 shares of the stock were exchanged, compared to its average volume of 156,760. The company has a current ratio of 0.99, a quick ratio of 0.76 and a debt-to-equity ratio of 0.77. The firm has a market capitalization of $21.16 billion, a P/E ratio of 15.17, a price-to-earnings-growth ratio of 2.56 and a beta of 1.46. The business has a 50-day moving average of $33.86 and a 200 day moving average of $37.91. Fresenius Medical Care AG & Co. has a fifty-two week low of $30.99 and a fifty-two week high of $53.04.

Fresenius Medical Care AG & Co. (NYSE:FMS) last posted its quarterly earnings data on Tuesday, July 30th. The company reported $0.52 earnings per share for the quarter, missing the consensus estimate of $0.55 by ($0.03). The firm had revenue of $4.88 billion for the quarter, compared to analyst estimates of $4.78 billion. Fresenius Medical Care AG & Co. had a return on equity of 10.18% and a net margin of 7.34%. As a group, research analysts forecast that Fresenius Medical Care AG & Co. will post 2.32 EPS for the current fiscal year.

Several brokerages have issued reports on FMS. BTIG Research downgraded Fresenius Medical Care AG & Co. from a “buy” rating to a “neutral” rating in a report on Thursday, August 1st. Royal Bank of Canada restated a “neutral” rating on shares of Fresenius Medical Care AG & Co. in a report on Monday, August 19th. Zacks Investment Research downgraded Fresenius Medical Care AG & Co. from a “hold” rating to a “sell” rating and set a $41.00 price target for the company. in a report on Monday, July 1st. DZ Bank restated a “neutral” rating on shares of Fresenius Medical Care AG & Co. in a report on Tuesday, July 30th. Finally, JPMorgan Chase & Co. restated a “buy” rating on shares of Fresenius Medical Care AG & Co. in a report on Thursday, August 29th. Two research analysts have rated the stock with a sell rating, five have issued a hold rating and four have assigned a buy rating to the company. Fresenius Medical Care AG & Co. has an average rating of “Hold” and an average target price of $53.05.

Fresenius Medical Care AG & Co. Profile

Fresenius Medical Care AG & Co KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services in Germany, the United States, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.

Featured Story: Convertible Shares

Want to see what other hedge funds are holding FMS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Fresenius Medical Care AG & Co. (NYSE:FMS).

Institutional Ownership by Quarter for Fresenius Medical Care AG & Co. (NYSE:FMS)

Receive News & Ratings for Fresenius Medical Care AG & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. and related companies with MarketBeat.com's FREE daily email newsletter.